GH:NSD-Guardant Health Inc (USD)

COMMON STOCK | Diagnostics & Research |

Last Closing

USD 18.88

Change

+0.30 (+1.61)%

Market Cap

USD 1.96B

Volume

1.12M

Analyst Target

USD 110.00
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-05-03 )

Largest Industry Peers for Diagnostics & Research

Symbol Name Price(Change) Market Cap
IDXX IDEXX Laboratories Inc

+2.51 (+0.46%)

USD 43.04B
ICLR ICON PLC

-1.11 (-0.35%)

USD 26.09B
ILMN Illumina Inc

-3.39 (-2.96%)

USD 18.41B
NTRA Natera Inc

-2.04 (-1.88%)

USD 12.93B
MEDP Medpace Holdings Inc

+0.02 (+0.01%)

USD 12.09B
EXAS EXACT Sciences Corporation

-1.57 (-3.02%)

USD 9.96B
RDNT RadNet Inc

-0.13 (-0.23%)

USD 4.19B
SHC Sotera Health Co

-0.12 (-1.05%)

USD 3.13B
OLK Olink Holding AB ADR

N/A

USD 2.90B
NEOG Neogen Corporation

+0.13 (+0.97%)

USD 2.67B

ETFs Containing GH

XMLH:F Legal & General Ucits Etf.. 1.77 % 0.00 %

N/A

USD 0.07B
DOCT:SW L&G Healthcare Breakthrou.. 1.77 % 0.00 %

N/A

USD 0.07B

Market Performance

  Market Performance vs. Industry/Classification (Diagnostics & Research) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -30.20% 25% F 18% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -30.20% 25% F 18% F
Trailing 12 Months  
Capital Gain -20.17% 55% F 33% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -20.17% 55% F 32% F
Trailing 5 Years  
Capital Gain -72.65% 37% F 19% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -72.65% 33% F 18% F
Average Annual (5 Year Horizon)  
Capital Gain -10.34% 40% F 26% F
Dividend Return -10.34% 40% F 26% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 51.88% 49% F 32% F
Risk Adjusted Return -19.93% 40% F 31% F
Market Capitalization 1.96B 80% B- 80% B-

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector